Author of

• 25958

  +

  P3.04 - Immunooncology (Not CME Accredited Session) (ID 970)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall

  • 27528

    +

    P3.04-18 - The Efficacy and Safety of Solid Tumors Combination Therapy with Immune Checkpoint Inhibitor: A Systematic Review and Meta-Analysis (ID 14405)

    12:00 - 13:30  |  Author(s): Qibin Song
    • Abstract
    • Slides

    Background
    

    The value of combination therapy with immune checkpoint inhibitor (ICI) for patients with solid tumors remains unclear. We conducted a meta-analysis to evaluated the combination therapy with immune checkpoint inhibitor (ICI) for patients with solid tumors.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    Pub-med, EMBASE, Cochrane Library and ClinicalTrials.gov website were searched for eligible randomized controlled trails (RCTs). The selection criteria were defined according to the PICOS (population, intervention, comparison, outcome and study design) framework. We assessed overall response rate (ORR), progression free survival (PFS), overall survival (OS) and grade 3 or 4 adverse effects (AEs). Pooled hazard ratio (HR) for survival outcomes (PFS and OS) and pooled risk ratio (RR) for dichotomous data (ORR and AEs) with 95% CI were calculated.

    4c3880bb027f159e801041b1021e88e8 Result
    

    17 RCTs with 6,616 patients were included in this meta-analysis. The combination therapy of ICI was signifcantly associated with improvement of ORR (RR = 1.56 [95% CI 1.24, 1.96], P = 0.0001), PFS (HR = 0.69 [95% CI 0.59, 0.81], P < 0.00001) and OS (HR = 0.76 [95% CI 0.67, 0.87], P < 0.0001) in solid tumor. In subgroup analyses, combination ICI therapy obviously prolonged OS in melanoma patients (HR = 0.64 [95% CI 0.57, 0.72], p<0.00001), but not in SCLC (HR = 0.94 [95% CI 0.82, 1.08], P = 0.40) and NSCLC (HR = 0.92 [95% CI 0.79, 1.07], P = 0.26) patients. As for toxicity, there was an increased risk of fatigue, rash, diarrhoea and increased transaminases with combination ICI therapy.

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    In conclusion, our meta-analysis found that combination ICI therapy showed significant benefits in ORR, PFS and OS for patients with solid tumors. Both of combination of ICI with chemoradiotherapy and dual ICI were effective and relatively safe. Melanoma patients got definite survival benefit from combinaiton ICI therapy. There was also a tendency of improvement of survival for SCLC and NSCLC patients.

    6f8b794f3246b0c1e1780bb4d4d5dc53

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.